AZOBACT

Each film coated tablets contains:

(Azithromycin Dihydrate IP equivalent to Azithromycin 250 mg / 500 mg

Tablet for Oral Use

Azithromycin inhibits protein synthesis in susceptible organisms by penetrating the cell wall and binding to 50 S ribosomal subunits, eventually inhibiting polypeptide synthesis. Azithromycin usually is bacteriostatic, although the drug may be bactericidal in high concentrations against selected organisms.

Absorption: The absolute oral bioavailability of Azithromycin is reported to be approximately 34–52% with single doses of 500 mg to 1.2 g administered as various oral dosage forms. 

Distribution: After oral administration, Azithromycin is widely distributed in tissues with an apparent steady-state volume of distribution of 31.1 L/kg

Protein Binding: The serum protein binding of Azithromycin varies in humans, decreasing from 51% at 0.02 g/mL to 7% at 2 g/ml

Metabolism &Excretion: Metabolized by the liver. Azithromycin is excreted in feces principally as unchanged drug

Half Life: The terminal elimination half-life (t_½) was up to 68 hrs.

• Lower  and Upper Respiratory Tract Infections
• Genito Urinary Tract Infections
• Pneumonia
• Otitis Media
• Urethritis &Cervicitis caused by Chlamydia trachomatis & Neisseria gonorrhoeae.

ADVERSE REACTION:

Common side effects may include: diarrhea, nausea, vomiting, stomach pain, and headache

DOSAGE AND ADMINISTRATION:

Generall Dosing Schedule: 500mg once daily for 3-5 Days

• Genital Ulcer Disease (Chancroid): Single 1g Dose
• Non – Gonococcal Urethritis & Cervicitis: Single 1g Dose